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ABSTRAK
Dispepsia merupakan salah satu dari berbagai keluhan umum yang dapat ditemui oleh dokter di berbagai 
bidang, tidak terbatas hanya pada ahli saluran cerna saja dalam praktik kesehariannya. Pengertian mengenai 
patofisiologi dispepsia terus berkembang sejak dimulainya investigasi secara ilmiah pada 1980-an sampai dengan 
saat ini yang memandang infeksi Helicobacter pylori sebagai salah satu faktor kunci dalam menangani dispepsia, 
baik terkait ulkus maupun non-ulkus. Penatalaksanaan dispepsia tidak bisa dilepaskan dari penatalaksaan infeksi 
H.pylori, serta penambahan pengetahuan baru terkait definisi, patofisiologi, diagnosis dan penatalaksanaan 
dispepsia dan infeksi H.pylori.
Konsensus penatalaksanaan dispepsia dan infeksi H.pylori di Indonesia ini dibuat berdasarkan evidence 
based medicine, sehingga dapat digunakan sebagai rujukan para dokter dalam menangani kasus-kasus dispepsia 
dan infeksi H.pylori di tempat praktik sehari-hari. Dengan adanya konsensus terbaru ini diharapkan para dokter 
dapat lebih meningkatkan pelayanannya kepada pasien-pasien dispepsia dan infeksi H.pylori.
Kata kunci: dispepsia, H. Pylori, saluran cerna.
ABSTRACT
Dyspepsia is one of numerous general complaints, which is commonly encountered by doctors of 
various disciplines. In daily practice, the complaint is not only limited for gastroenterologists. Knowledge 
on pathophysiology of dyspepsia have been developing continuously since a scientific investigation has been 
started in 1980’s, which considers Helicobacter pylori as one of key factor in managing dyspepsia, either it is 
associated with ulcer or non-ulcer. The management of dyspepsia cannot be separated from the management 
of H. pylori and there is an additional new knowledge associated with definition, pathophysiology, diagnosis 
and treatment of both dyspepsia and H. pylori infection.
This consensus document on the management of dyspepsia and H. pylori infection in Indonesia has been 
developed using the evidence-based medicine principles; therefore, it can be used as a reference for doctors 
in dealing with dyspepsia and H. pylori infection cases in their daily practice. It is expected that with the new 
consensus, doctors can provide greater service to their patients who have dyspepsia and H. pylori infection.
Keywords: dyspepsia, H. Pylori, gastrointestinal tract.
Ari F. Syam                                                                                                           Acta Med Indones-Indones J Intern Med
280
INTRODUCTION
Dyspepsia is a common symptom found 
in daily practice and it has been known for a 
long period of time. There is a continuously 
developing definition starting from all symptoms 
originated from the upper gastrointestinal tract 
up to the exclusion of reflux symptoms; while 
the most recent definition refers to the Rome 
III criteria.1
H. pylori (Hp) infection nowadays has 
been considered as one of important factors 
in dyspepsia management, both the organic or 
functional dyspepsia; therefore, any discussion 
on dyspepsia should be correlated with the 
management of Hp infection. Various meta-
analysis studies have demonstrated that there 
is a correlation between Hp infection and 
gastroduodenal diseases, which is characterized 
by symptoms/signs of dyspepsia.2,3 The 
prevalence of Hp infection in Asia is relatively 
high and thus it should be noticed in the diagnosis 
approach and management of dyspepsia. 
Hp eradication has been proven effective in 
eliminating symptoms of organic dyspepsia; 
however, for functional dyspepsia, further studies 
are still necessary.4
The consensus is developed to provide a 
guideline for general physicians, specialists, 
and consultants regarding the management of 
dyspepsia. The consensus has combined the 
management of dyspepsia and Hp infection; 
therefore, it will achieve better results.
EPIDEMIOLOGY
Dyspepsia is an uncomfortable feeling 
(discomfort) originated from the upper part of 
abdomen. The discomfort can be one of or some 
of following symptoms, i.e. epigastric pain, 
epigastric burn, feeling of fullness after having 
meal, early satiated and bloating in the upper 
gastrointestinal tract area, nausea, vomiting 
and blurping.5 For functional dyspepsia, those 
abovementioned symptoms must occur for at 
least the last three months with symptom onset 
of six months before the diagnosis is defined.
The prevalence of dyspepsia in health 
care units reaches 30% of services offerec by 
general physicians and 50% of services by 
gastroenterologists. Most of Asian patients 
with uninvestigated dyspepsia and without any 
alarm signs experience functional dyspepsia. 
The results of studies in Asian countries (China, 
Hong Kong, Indonesia, Korea, Malaysia, 
Singapore, Taiwan, Thailand and Vietnam) show 
that 43 to 79.5% patients with dyspepsia have 
dysfunctional dyspepsia.5
From the results of endoscopy, which had 
been performed in 550 patients with dyspepsia 
at some centers in Indonesia between January 
2003 and April 2004, there were 44.7% cases 
with minimal disorder of gastritis and duodenitis; 
6.5^ cases with gastric ulcer and 8.2% of normal 
cases.6 In Indonesia, the data on prevalence of Hp 
infection in patients with peptic ulcers (without 
a history of using non-steroid anti-inflammatory 
drugs (NSAIDS)) varies between 90 and 100% 
and for patients with functional dyspepsia, the 
prevalence is 20-40% with various diagnostic 
methods (serology examination, culture and 
histopathology).7
The prevalence of Hp infection in patients 
with dyspepsia who underwent endoscopic 
examination at various teaching hospital in 
Indonesia between 2003 and 2004 was 10.2%. 
A relatively high prevalence was found in 
Makassar, which was 55% (2011) and in Solo as 
many as 51.8% (2008). The high prevalence was 
also found in Yogyakarta of 30.6% and Surabaya 
of 23.5% in 2013; while the lowest prevalence 
has been found in Jakarta (8%).6,8-10
PATHOPHYSIOLOGY
The pathophysiiology of peptic ulcer caused 
by Hp and non-steroid anti-inflammatory drugs 
(NSAID) has been widely known.1 Functional 
dyspepsia is caused by some major factors 
such as gastroduodenal motility disorder, Hp 
infection, gastric acid, visceral hypersensitivity 
and psychological factors. Other factors that may 
have role are genetics, life style, environment, 
diet and history of previous gastrointestinal 
infection.11,12
The Role of Gastroduodenal Motility Disorders 
The gastroduodenal motility disorder consists 
of reduced gastric capacity in accommodating 
meal (impaired gastric accommodation), 
antroduodenal incoordination and slow gastric 
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emptying. It is also one of main mechanism in the 
pathophysiology of functional dyspepsia, which 
is associated with bloating after meal and it may 
be found in the form of abdominal distension, 
bloating and fullness.5,12
The Role of Visceral Hypersensitivity
Visceral hypersensitivity has an important role 
in the pathophysiology of functional dyspepsia, 
particularly in increasing the sensitivity of 
peripheral and central sensory nerves against 
chemical and intraluminal receptor stimuli at 
the proximal part of the stomach. It can cause 
or aggravate dyspepsia symptoms.5
The Role of Psychosocial Factors
Psychosocial disorder is one of inducers 
that may have roles in functional dyspepsia. The 
severity of psychosocial disorder is consistent 
with the severity of dyspepsia. Various studies 
show that depression and anxiety have roles in 
the development of functional dyspepsia.5,12
The Role of Gastric Acid
Gastric acid may have a role in developing 
symptoms of functional dyspepsia. It has also 
becomes an underlying reason for effective 
treatment using anti-secretory agents as shown 
by some studies in patients with functional 
dyspepsia. There is little data of studies on the 
gastric secretion and some reports in Asia are 
still controversial.5
The Role of Hp Infection
The prevalence of Hp infection in patients 
with functional dyspepsia varies from 39% to 
87%. The correlation between Hp infection 
and motility disorder is inconsistent; however, 
eradication of Hp improves the symptoms of 
functional dyspepsia. Biological markers such as 
ghrelin and leptin as well as altered expression 
of muscle-specific microRNAs are correlated 
with pathophysiological process of functional 
dyspepsia, which still needs further studies.5,13
DIAGNOSIS
Diagnosis of Dyspepsia
Dyspepsia that has been investigated consists 
of organic and functional dyspepsia. Organic 
dyspepsia consists of gastric ulcer, duodenal 
ulcer, erosive gastritis, gastritis, duodenitis and 
a process of malignancy. Functional dyspepsia 
refers to the Rome III criteria, which has not 
been validated in Indonesia. The Asia-Pacific 
Consensus (2012) has decided to follow the 
concept in the Rome III diagnosis criteria with 
some additional symptoms of bloating in the 
upper abdominal part, which is commonly found 
as the symptom of functional dyspepsia.5
Dyspepsia according to the Rome III 
criteria is a disease with one or more symptoms 
associated with gastroduodenal abnormalities of: 
• Epigastric pain
• Epigastric burn sensation
• Fullness or discomfort after meal
• Early satiety
The symptoms must occur at least in the last 
three months with an onset of symptoms in six 
months before the diagnosis is established.
The Rome III criteria categorize functional 
dyspepsia into 2 subgroups, i.e. the epigatric pain 
syndrome and postprandial distress syndrome. 
However, the most recent evidence demonstrates 
that there is an overlapping of diagnosis in two 
third of patients with dyspepsia.1
Uninvestigated dyspepsia
Workups (consistent with indications)
- Blood test
- Endoscopy
- Urea breath test
- Abdominal USG
Functional dyspepsia- Organic dyspepsia
- Peptic ulcer
- Erosive gastritis







Figure 1. Algorithm for diagnosis of uninvestigated dyspepsia
Evaluation on the alarm signs must always 
be part of evaluation of the patients who come 
with a complaint of dyspepsia. The alarm signs 
for dyspepsia include weight loss (unintended 
weight loss), progressive dysphagia, recurrent 
or persistent vomiting, gastrointestinal bleeding, 
anemia, fever, a mass in the upper abdominal 
area, a family history of gastric cancer, dyspepsia 
with new onset in patients aged more than 45 
years. Patients with those complaints must be 
investigated first using endoscopy.5
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Diagnosis of Hp Infection14
Diagnostic test of Hp infection can be 
performed both directly using endoscopy (rapid 
urease test, histological test, culture and PCR) and 
indirectly without endoscopy (urea breath test, 
stool test, urine test and serology). Urea breat test 
has now become the gold standard for evaluating 
Hp. One of the available urea breath tests is the 
13CO breath analyzer. There is a requirement for 
conducting Hp evaluation, i.e. the patient must 
be free from antibiotic and PPI (proton-pump 
inhibitor) treatment for 2 weeks and there are 
some other factors that need to be taken into 
consideration such as clinical situation, prevalence 
of the infection, prevalence of the infection in 
a population, probability of pre-test infection, 
differences in test performance and factors that 
can affect the result of the test such as the use of 
anti-secretory and antibiotic treatment.
MANAGEMENT
The management of dyspepsia is initiated 
by carrying out efforts on identification of 
pathophysiology and etiological factors as 
many as possible.11 Treatment of dyspepsia 
can already be started based on the dominant 
clinical symptoms (although those symptoms 
have not been investigated) and the treatment 
is subsequently continued in consistent with the 
results of investigation.
Tabel 1. A comparison of various diagnostic tests for Hp infection
Tests Sn Sp Notes
With endoscopy
Rapid urease test >98% 99%
 - Fast and inexpensive
 - Reduced sensitivity following treatment
 - Specimens are obtained from antrum
Histology >95% >95%
 - Increased detection using special staining 
Warthin- Starry/ hematoxylin-eosin/ Giemsa)
 - Specimens are obtained from antrum and corpus
Culture
 - Very specific, poor sensitivity when transport medium is not 
available
 - Requires experience
 - Expensive, often unavailable
 - Specimens are obtained from antrum and corpus
 - Using media such as Sparrow
PCR
 - Sensitive and specific
 - No standard
 - Specimens were obtained from antrum and corpus
 - Considered
Without endoscopy
ELISA serology 85-92% 79-83%
 - Less accurate and does not demonstrate active infection
 - A reliable predictor of infection in developing countries with 
high prevalencei
 - It is not recommended for a period after therapy
 - Inexpensive and  available
13C urea breath test (UBT) 
such as: 13CO2 breath 
analyzer
95% 96%
 - It is recommended for establishing the diagnosis of Hp 
infection before commencing therapy14
 - The test of choice for confirming eradication
 - Patient is not allowed having PPI and antibiotic treatment for 
2 weeks prior to the examination.15,16
 - Varied availability
Fecal antigen 95% 94% Rarely used although it has high sensitivity and specificity, before and after therapy
Finger-stick serology Very poor and can not match the ELISA serology
Urinary antibody: Urine-
baed Rapid Urine Test17-19 73.2-82% 78.6-90.7%
Right now, the urine test has not been available in Indonesia 
Sn:  sensitivity,  Sp:  specificity,  ELISA:  enzyme-linked  immunosorbent assay,
PCR: polymerase chain reaction, PPI: proton-pump inhibitor
Vol 49 • Number 3 • July 2017                       National consensus on management of dyspepsia and H. pylori infection
283
Uninvestigated Dyspepsia
The optimum management strategy for 
this phase is by providing empirical therapy 
for 1-4 weeks before receiving results of initial 
investigation, i.e. the examination evaluating 
the evidence of Hp presence.11,13 For certain 
region and ethnicity and patients with high risk, 
the Hp evaluation must be performed earlier. 
Medications that can be used are antacids, 
gastric acid antisecretory agents (PPI such as 
omeprazole, rabeprazole and lansoprazole and/
or H2-Receptor Antagonist [H2RA]), prokinetics 
and cytoprotectors (such as rebamipide), in 
which the selection of the regimen is based on the 
dominant symptoms and previous medication. 
There is an ongoing development of a new drug 
which acts on the down-regulation proton pump 
that has been expected to have better mechanism 
of action than the PPI, i.e. the DLBS.24,11
Associated with the high prevalence of Hp 
infection, the test-and-treat strategy is applied 
for patients with dyspepsia symptoms without 
any alarm sign. The test-and-treat strategy is 
performed for:20
• Dyspepsia patients without any complication, 
who do not response to life style changes, 
2-4 weeks of treatment using single PPI and 
without any alarm sign. 
• Patients with a history of gastric or duodenal 
ulcer, but have never been investigated. 
• Patients who will receive NSAID, particularly 
those with a history of gastroduodenal ulcer. 
• Patients with unexplained iron deficiency 
anemia, idiopathic thrombocytopenic 
purpura and vitaminB12 deficiency.
Test and treat is NOT performed in:20
• Patients with gastroesophageal reflux disease 
(GERD).
• Children with functional dyspepsia.
Dyspepsia That Has Been Investigated
Dyspepsia patients with alarm signs receive 
no empirical therapy; instead, they should be 
investigated first by endoscopy with or without 
histopathological assessment before they are 
treated as patients with functional dyspepsia.
After the investigation, it does not exclude 
the possibility that in some of dyspepsia cases, 
GERD is found as the abnormality.
Organic Dyspepsia
When a lesion of mucosa (mucosal 
damage) is found, which is consistent with 
the endoscopy findings, therapy is given based 
on the abnormalities that have been found. 
Abnormalities that have been included into 
the organic dyspepsia group are gastritis, 
hemorrhagic gastritis, duodenitis, gastric ulcer, 
duodenal ulcer or malignancy process. In 
peptic ulcer (gastric and/or duodenal ulcer), the 
medication that can be given are  a combination 
of PPI such as rabeprazole 2 x 20 mg or 
Table 2. Therapy regimen for Hp eradication14,23
Drug Dose Duration
First line:
PPI* 2x1 7-14 days
Amoxicillin 1000 mg (2x1)
Clarithromycin 500 mg (2x1)
In an area where resistance to clarithromycin >20%
PPI* 2x1 7-14 days
Bismuth 
subsalicylate 2x2 tablet
Metronidazole 500 mg (3x1)
Tetracyline 250 mg (4x1)
When bismuth is not available:
PPI* 2x1 7-14 days
Amoxicillin 1000 mg (2x1)
Clarithromycin 500 mg (2x1)
Second line: this class of drugs is used when there is a 
failure with clarithromycin-based regimen
PPI* 2x1 7-14 days
Bismuth 
subsalicylate 2x2 tablets
Metronidazole 500 mg (3x1)
PPI* 2x1 7-14 days
Amoxicillin 1000 mg (2x1)
Levofloxacin 500 mg (2x1)
Third line: when the second line regimen fails. 
Whenever possible, the selection is based on resistance 
test and/or clinical changes
PPI* 7-14 days
Amoxicillin 2x1
Levofloxacin 1000 mg (2x1)
Rifabutin 500 mg (2x1)
*PPI agents that have been used are rabeprazole 20 mg, 
lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 
mg and esomeprazole 40   mg.
Notes: Sequential therapy (can be given as the first lilne 
when there is no data about resistance to clarithromycin): 
PPI + amoxicillin for 5 days followed by PPI + clarithromycin 
and nitroimidazole (tinidazole) for 5 days.
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lanzoprazole 2 x 30 mg and mucoprotectors such 
as rebamipide 3 x 100 mg.
Functional Dyspepsia
When there is no mucosal damage found 
after the investigation, the treatment can be given 
in consistent with the presence of functional 
dyspepsia.
The use of prokinetics such as metoclopramide, 
domperidone, cisapride, itopride and others 
can improve the symptoms of patients with 
functional dyspepsia. It may be associated with 
slow gastric emptying as one of pathophysiology 
in functional dyspepsia. Caution must always 
be applied when using cisapride as it may have 
potency for cardiovascular complication.11
Data about the use of antidepressants 
or antianxiolytic in patient siwht functional 
dyspepsia is still very limited. A recent study in 
Japan has demonstrated a significant improved 
symptom in patients with functional dyspepsia 
who have receivied 5-HT1 agonists compared to 
placebo. On the other hand, the use of venlafaxin, 
a serotonine and norepinephrin inhibitor, does 
not show better results compared to placebo.5
Psychological problems as well as sleep 
disturbance and defects on central serotonin 
sensitivity may become important factors in the 
response of antidepressant therapy in patients 
with functional dyspepsia.5
Management of dyspepsia with Hp infection
Hp eradication can provide long-term 
remission of dyspepsia symptoms.20 A cross-
sectional study conducted in 21 patients at Cipto 
Mangunkusumo Hospital, Jakarta (2010) found 
that the eradication therapy had improved the 
symptoms in a majority of dyspepsia patients 
with a percentage of symptom improvement as 
much as 76% and 81% had negative Hp results 
when they were evaluated using UBT.21
Figure 2. Algorithm of managing dyspepsia at various levels of health care units5
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*Alarm signs: weight loss (unintended) progressive dysphagia, recurrent/persistent vomiting, 
gastrointestinal tract bleeding, anemia, fever, upper abdominal mass, family history of stomach 
cancer, new onset dyspepsia in patients aged >45 years.
PE: physical examination; UGIT: Upper Gastro Intestinal Tract, HCP-1: The First Level Health 
Care Provider, HCP-2-3: The Second and Third Level of Health Care Providers.
Figure 3. Algorithm of managing functional dyspepsia5
A prospective study conducted by Syam AF 
et al in 2010 showed that Hp eradication therapy 
using triple therapy (rabeprazole, amoxicillin 
and clarithromycin) for 7 days was better than 
the 5-day therapy.22
In an area where resistance to clarithromycin 
is high, we recommend to perform culture and 
resistance test (using endoscopic specimens) 
prior to therapy. A molecular test can also 
be performed to detect Hp and resistance to 
clarithromycin and/or fluoroquinolone directly 
through gastric biopsy.
After giving eradication therapy, a 
confirmation test must be done using UBT or 
H. pylori stool antigen monoclonal test. The test 
can be performed within at least 4 weeks after the 
end of treatment. For HpSA, there is a possibility 
of false positive result.
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Figure 4. Algorithm of managing eradication of Hp infection5
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